** Shares of cancer therapy maker Legend Biotech LEGN.O rise 4.2% to $41.25 premarket
** Partner Johnson & Johnson JNJ.N reports Q2 sales of blood cancer cell therapy Carvykti of $439 mln vs consensus estimates of $419 mln
** JNJ says Carvykti increase is driven by continued share gains and capacity expansion
** "We look to continued growth in 2H25, and expect revenue to accelerate given a typically strong back half, especially with additional production likely to come online,"- brokerage RBC Capital Markets
** We like that Carvykti continues to grow at ~19% quarter over quarter, suggesting there is still untapped demand in the myeloma market, which can enable further growth in 2H25 and 2026, brokerage says
** Up to last close, LEGN up 21.7% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.